Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04832087 · ClinicalTrials.gov registry record
Pediatric Teduglutide Registry
A clinical trial of Short Bowel Syndrome, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 142
- Enrollment target
- 1
- Study location
NCT04832087: Completed study of Short Bowel Syndrome, sponsored by Boston Children's Hospital.
NCT04832087 is a study of Short Bowel Syndrome that has completed, run by Boston Children's Hospital. The registered enrollment target is 142 participants, below the 176-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04832087, a study of Short Bowel Syndrome, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
Pediatric specific post-marketing registry to evaluate the long-term safety and efficacy of teduglutide.
Primary Outcome
Maximum percent change in calories (energy intake in kcal/kg/day) from parenteral support relative to pre- treatment (baseline) assessment up to 6 months, 1 year, 2 years and 3 years from start of therapy among Cohort A.
Conditions Studied
Interventions
- DRUG Teduglutide
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2023-08-31 |
What the finished NCT04832087 record still lists
NCT04832087 is an observational study that tracks outcomes without assigning an intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 176-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Teduglutide is the first listed.
NCT04832087 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04832087 about?
NCT04832087 is a clinical study titled "Pediatric Teduglutide Registry". Pediatric specific post-marketing registry to evaluate the long-term safety and efficacy of teduglutide.
What is the current status of trial NCT04832087?
This trial is currently completed. The enrollment target is 142 participants. The study started on 2021-05-18. Estimated completion is 2023-08-31.
What conditions does trial NCT04832087 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
What interventions are being tested in trial NCT04832087?
The interventions under investigation include: Teduglutide (DRUG).
Who is sponsoring clinical trial NCT04832087?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04832087 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04832087's enrollment target sits among peer trials
142 5th of 17 higher than 13 of 17 other Short Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Short Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
RECRUITING · NA
-
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
RECRUITING · Early Phase 1
-
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
RECRUITING · Phase 2
-
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
RECRUITING · NA
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Registry for Participants With Short Bowel Syndrome
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI